Drug Trial Radar · NCT07905157
A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Nov 3, 2026
Primary completion
Mar 30, 2027
Study completion Mar 30, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label study being done to compare two different methods of study medicine bepirovirsen is given in healthy adults. The researchers want to learn how the body affects the medicine over time (pharmacokinetic \[PK\] study). The study will also evaluate the safety of bepirovirsen and how well it is tolerated, meaning how people feel after receiving the medicine and whether they experience any side effects.
Conditions
- Hepatitis B
Interventions
BepirovirsenDrug
Bepirovirsen will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-time Curve from Time Zero (pre-dose) up to Day 8 [AUC(0- 8 d)] of Bepirovirsen in PlasmaTime frame: Pre-dose to Day 8 (168 hours) post dose
- Maximum Observed Concentration (Cmax) of Bepirovirsen in plasmaTime frame: Pre-dose to Day 8 (168 hours) post dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.